Literature DB >> 11509687

Integrated end-stage renal disease care: the role of peritoneal dialysis.

P G Blake1.   

Abstract

This paper reviews the rationale behind the proposed policy of using peritoneal dialysis (PD) as the initial treatment modality in patients with end-stage renal disease (ESRD). The better preservation of residual renal function associated with PD is emphasized along with its potential cardiovascular benefits. The superior patient survival on PD, relative to hemodialysis, during the first 2 years on dialysis in both the United States and Canada is discussed, as are the potential advantages of PD in terms of hepatitis C prevention, anaemia management and quality of life. The lower cost of PD in association with these clinical advantages lead to the modality being more cost-effective in the early years on dialysis. The relatively high technique failure rate on PD, however, subsequently leads to an increasing need for haemodialysis. A policy of integrated dialysis care with PD first and then haemodialysis, as required, is advocated as a more cost-effective approach to ESRD in suitable patients.

Entities:  

Mesh:

Year:  2001        PMID: 11509687     DOI: 10.1093/ndt/16.suppl_5.61

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  22 in total

1.  The relationship between the soluble Klotho protein and the residual renal function among peritoneal dialysis patients.

Authors:  Tetsu Akimoto; Kazuhiro Shiizaki; Taro Sugase; Yuko Watanabe; Hiromichi Yoshizawa; Naoko Otani; Akihiko Numata; Eri Takeshima; Tomoyuki Yamazaki; Takuya Miki; Chiharu Ito; Johanne V Pastor; Yoshitaka Iwazu; Osamu Saito; Shigeaki Muto; Makoto Kuro-o; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2012-02-18       Impact factor: 2.801

Review 2.  [Peritoneal dialysis--an ideal initial dialysis mode].

Authors:  Heidi Puttinger
Journal:  Wien Med Wochenschr       Date:  2013-07-02

Review 3.  Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions.

Authors:  Ahad Qayyum; Elizabeth Ley Oei; Klara Paudel; Stanley L Fan
Journal:  World J Nephrol       Date:  2015-02-06

4.  Effects of a pre-dialysis patient education program on the relative frequencies of dialysis modalities.

Authors:  Werner Ribitsch; Bernd Haditsch; Ronald Otto; Gernot Schilcher; Franz Quehenberger; Johannes M Roob; Alexander R Rosenkranz
Journal:  Perit Dial Int       Date:  2013-04-01       Impact factor: 1.756

5.  Effect of an educational program on the predialysis period for patients with chronic renal failure.

Authors:  Daijo Inaguma; Miho Tatematsu; Hibiki Shinjo; Sachiyo Suzuki; Tomoko Mishima; Shinichiro Inaba; Kei Kurata
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

6.  Endoplasmic reticulum stress as a novel target to ameliorate epithelial-to-mesenchymal transition and apoptosis of human peritoneal mesothelial cells.

Authors:  Hyun-Soo Shin; Eun-Sun Ryu; Eok-Soo Oh; Duk-Hee Kang
Journal:  Lab Invest       Date:  2015-07-20       Impact factor: 5.662

7.  Is transition between peritoneal dialysis and hemodialysis really a gradual process?

Authors:  Lucie Boissinot; Isabelle Landru; Eric Cardineau; Elie Zagdoun; Jean-Philippe Ryckelycnk; Thierry Lobbedez
Journal:  Perit Dial Int       Date:  2013-01-02       Impact factor: 1.756

Review 8.  Icodextrin: a review of its use in peritoneal dialysis.

Authors:  James E Frampton; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Home dialysis as a first option: a new paradigm.

Authors:  Dimitrios G Oreopoulos; Elias Thodis; Ploumis Passadakis; Vassilis Vargemezis
Journal:  Int Urol Nephrol       Date:  2009-05-09       Impact factor: 2.370

10.  Health economic evaluation of peritoneal dialysis based on cost-effectiveness in Japan: a preliminary study.

Authors:  Tomoyuki Takura; Makoto Hiramatsu; Hidetomo Nakamoto; Takahiro Kuragano; Jun Minakuchi; Hironori Ishida; Masaaki Nakayama; Susumu Takahashi; Hideki Kawanishi
Journal:  Clinicoecon Outcomes Res       Date:  2019-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.